Showing results (901-910 of 967) with videos related to
Sort By:
Pageof 97
European Heart Journal. Cardiovascular Pharmacotherapy|November 11, 2020
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trialMasanori Asakura, Shin Ito, Takahisa Yamada, et al.Cancer Medicine|December 15, 2022
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology International|September 8, 2022
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumabTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Nutrients|July 11, 2023
Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver DiseaseHirokazu Takahashi, Miwa Kawanaka, Hideki Fujii, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 6, 2023
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysisTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.Liver Cancer|August 21, 2023
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter AnalysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology International|June 24, 2022
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|January 18, 2020
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from JapanHidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe, et al.Pageof 97